Mirabegron in the Management of Overactive Bladder Syndrome
Miriam O'Kane,1 Dudley Robinson,1 Linda Cardozo,1 Adrian Wagg,2 Paul Abrams3 1Department of Urogynaecology, King's College Hospital, London, UK; 2Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 3Bristol Urological Institute, Bristol, UKCorrespondence: Dudley Robin...
Saved in:
Main Authors: | O'Kane M (Author), Robinson D (Author), Cardozo L (Author), Wagg A (Author), Abrams P (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives
by: Robinson D, et al.
Published: (2023) -
Mirabegron: pharmacoeconomic aspects of the use of the drug for the treatment of overactive bladder syndrome
by: O. I. Ivakhnenko, et al.
Published: (2022) -
Profile of mirabegron in the treatment of overactive bladder: place in therapy
by: Sharaf A, et al.
Published: (2017) -
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
by: Luisa Gracio Ferreira Sartori, et al.
Published: (2023) -
Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder
by: I. N. Dyakov, et al.
Published: (2021)